Combination therapy with an anti - CD19 antibody and a nitrogen mustard

Combination therapy with an anti - CD19 antibody and a nitrogen mustard

  • CN 103,732,252 A
  • Filed: 08/14/2012
  • Published: 04/16/2014
  • Est. Priority Date: 08/16/2011
  • Status: Active Application
First Claim
Patent Images

1. one kind is used for the treatment of non_hodgkin lymphoma, the CD19 specific antibody of chronic lymphocytic leukemia and/or acute lymphoblastic leukemia and the synergistic combination of bendamustine, described specific antibody comprises and comprises sequence SYVMH(SEQ ID NO:

  • 1) HCDR1 district, sequence NPYNDG(SEQ ID NO;

    2) HCDR2 district, sequence GTYYYGTRVFDY(SEQ ID NO;

    3) HCDR3 district, sequence RSSKSLQNVNGNTYLY(SEQ ID NO;

    4) LCDR1 district, sequence RMSNLNS(SEQ ID NO;

    5) LCDR2 district and sequence MQHLEYPIT(SEQ ID NO;

    6) the antibody of antibody cross competition in LCDR3 district.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×